Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Seres Therapeutics (MCRB) over the last 6 years, with Q1 2025 value amounting to $8.7 million.

  • Seres Therapeutics' Shares Outstanding (Diluted Average) rose 1929.73% to $8.7 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.7 million, marking a year-over-year increase of 1929.73%. This contributed to the annual value of $155.4 million for FY2024, which is 2140.37% up from last year.
  • According to the latest figures from Q1 2025, Seres Therapeutics' Shares Outstanding (Diluted Average) is $8.7 million, which was up 1929.73% from $155.4 million recorded in Q4 2024.
  • Over the past 5 years, Seres Therapeutics' Shares Outstanding (Diluted Average) peaked at $155.4 million during Q4 2024, and registered a low of $7.3 million during Q1 2024.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $102.0 million, with a median of $108.1 million in 2022.
  • In the last 5 years, Seres Therapeutics' Shares Outstanding (Diluted Average) soared by 4074.5% in 2023 and then plummeted by 9419.6% in 2024.
  • Seres Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $91.7 million in 2021, then increased by 17.86% to $108.1 million in 2022, then increased by 18.44% to $128.0 million in 2023, then rose by 21.4% to $155.4 million in 2024, then tumbled by 94.39% to $8.7 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $8.7 million in Q1 2025, compared to $155.4 million in Q4 2024 and $152.6 million in Q3 2024.